Synonyms: SBC-115337
Compound class:
Synthetic organic
Comment: SBC-115,337 is an orally bioavailable small molecule from Shifa Biomedical's patent WO2017222953A, in which it is claimed as an inhbitor of the proprotein convertase subtilisin kexin type 9 (PCSK9)/low density lipoprotein receptor (LDLR) protein-protein interaction as a novel mechanism to control dyslipidemia [1-2]. This compound offers a first-in-class oral lead for hypercholesterolemia and more generally cardiovascular disease. In the absence of formal name-to-structure disclosure, we can speculate that SBC-115,337 may be P-21 as discussed in Shifa's press release of May 2021 (link here), based on SBC-115,337 being taken into in vivo testing. Shifa are partnering with Xontogeny to progress P-21 to clinical trial.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
SBC-115,337 upregulates functional LDLR in vitro, and reduces LDL-cholesterol levels by ~90% in mice fed high-fat diet [1]. |
Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|